Journal of Virus Eradication

Article	Citations
Impact of COVID-19 on people living with HIV: A review	62
Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, I	61
Altruism: Scoping review of the literature and future directions for HIV cure-related research	16
Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers	14
Re-examining the HIV ‘functional cure’ oxymoron: Time for precise terminology?	11
A viewpoint: The 2022 monkeypox outbreak	11
Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom	11
Achievements and gaps to provide pre-exposure prophylaxis (PrEP) for women across the European Region – Results from a European survey study	11
Vaccination with inactivated virus against low pathogenic avian influenza subtype H9N2 does not prevent virus transmission in chickens	9
Langya virus outbreak in China, 2022: Are we on the verge of a new pandemic?	9
A landscape analysis of HIV cure-related clinical research in 2019	8
Time for revolution? Enhancing meaningful involvement of people living with HIV and affected communities in HIV cure-focused science	8
The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review	8
Antiviral strategies targeting herpesviruses	7
Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers	7
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper	7
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study	7
Bringing social context into global biomedical HIV cure-related research: An urgent call to action	6
Comparison of methods to quantify inducible HIV-1 outgrowth	6
Antiviral activity of silver nanoparticles against the influenza A virus	6
Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis	6
Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women's perceptions, barriers and preferences	6
Motivations, barriers and experiences of participants in an HIV reservoir trial	6
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies	5
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV	5

Hepatitis C in Uganda: Identification of infected blood donors for micro-elimination	5
Substantial uneven proliferation of CD4+ T cells during recovery from acute HIV infection is sufficient to explain the observed expanded clones in the HIV reservoir	5
Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research	5
Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China	5
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection	5
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications	5
Bispecific antibody-derived molecules to target persistent HIV infection	4
Hypothetical questionnaires may overestimate willingness to participate in HIV cure research: Comparison of a cross-sectional survey to actual willingness to participate in an HIV cure study in the Ne	4
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection	4
Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness mo	4
Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform	4
Impact of hepatitis B vaccination programs in Vietnam evaluated by estimating HBsAg prevalence	4
Menopause care in women living with HIV in the UK - A review	3
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2	3
Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China	3
Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection	3
A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France	3
Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling	3
Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model	3
Influenza A (H6N6) viruses isolated from chickens replicate in mice and human lungs without prior adaptation	3
High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era	3
Combination strategies to durably suppress HIV-1: Soluble T cell receptors	3
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir	3
Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses	3
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV	2
Antiviral activity of nitazoxanide against Morbillivirus infections	2
OP 3.7 – 00099 Cohort-specific Adaptation of the Intact Proviral DNA Assay (IPDA) to HIV-1 subtypes A1, D, and recombinants	2
Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy	2
Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study	2
Heat shock protein: a double-edged sword linking innate immunity and hepatitis B virus infection	2
Is the human T-cell lymphotropic virus type 2 in the process of endogenization into the human genome?	2
OP 7.3 – 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345	2
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting	2
OP 3.4 – 00197 Infected naïve CD4+ T cells in children with HIV can proliferate and persist on ART	2
Mass immunisation to eradicate Japanese encephalitis: Real-world evidence from Guizhou Province in 2005–2021	2
Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice	2
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA	2
Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018	2
OP 6.2 – 00195 Targeted genome engineering of human t cells in vivo for HIV cure	1
The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection	1
OP 3.6 – 00023 Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation	1
Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand	1
Assessment of dengue virus threat to blood safety and community health: A single center study in northern Egypt	1
Engagement of AKT and ERK signaling pathways facilitates infection of human neuronal cells with West Nile virus	1
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral	1
OP 6.8 – 00102 In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-eCD4-Ig therapy	1
OP 3.1 HIV Persistence in women, an update	1
OP 3.5 – 00152 HIV-1RNA+infected CD4 T cell burden in acute HIV-1 infection and association with inflammatory markers	1
OP 1.1 Sequencing HIV: Significance and Impact	1
OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR tri	1

Key highlights from the international AIDS society (IAS) conference 2021	1
Intact provirus and integration sites analysis in acute HIV-1 infection and changes after one year of early antiviral therapy	1
OP 1.6 – 00138 Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms	1
OP 5.3 – 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption	1
OP 6.1 It's a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure	1
OP 6.4 – 00096 High-efficiency CRISPR/Cas9-mediated disruption of ccr5 in human hematopoietic stem progenitor cells generates HIV-refractory immune systems	1
Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa	1
OP 3.3 – 00030 Inducible replication-competent HIV proviruses persist in memory CD4+ T cells expressing high levels of the integrin VLA-4 (α4β1)	1
The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample	1
OP 3.2 – 00056 Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management	1
The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture	1
OP 8.4 – 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption	1
OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir	1
OP 6.6 – 00134 Viral Suppression in SHIV-infected Rhesus Macaques following AAVmediated Delivery of Closer-to-germline Monoclonal Antibodies	1
OP 8.3 – 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccin	1
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach	1
OP 1.7 – 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir	1
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings	1
Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents	1
OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs	1
OP 7.2 – 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial	1
OP 8.5 – 00104 TGF-beta Blockade to Stop HIV White Noise: a New “Release and Kill” HIV Strategy	1
OP 3.8 – 00066 Characterization of the HIV-1 viral reservoir in subtype B early treated individuals	1
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium	1
Patient acceptability of, and attitudes towards, hepatitis B cure research – A scoping review and identification of knowledge gaps	1
Commentary title: COVID-19 research, Africa, and global health	1
OP 7.4 – 00012 Series of Jojo. A way to disseminate HIV Cure information in a community language	1
OP 1.4 – 00053 Definitive evidence of a persistent HIV reservoir in human brain myeloid cells despite ART	1
The ethical case for placebo control in HIV-cure-related studies with ART interruption	1
OP 8.6 – 00166 Autologous neutralizing antibody responses in bnAb-treated rhesus macaques	1
OP 6.3 – 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia	1
OP 1.2 – 00157 HIV Silencing and Cell Survival Signatures of HIV-Infected CD4 T Cell Transcriptomes under Antiretroviral Therapy (ART)	1
OP 8.2 – 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection	1
OP 2.8 – 00193 Enhancing PKC Modulator HIV Latency Reversing Agents	1
OP 1.5 – 00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment	1
OP 1.10 – 00210 Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART	1
OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia	1
OP 6.7 – 00044 Long-term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques	1
PP 1.44 – 00107 Longitudinal evaluation of epigenetic age among people living with HIV (PLWH) undergoing multimodal curative interventions	0
PP 1.10 – 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir	0
Editorial JVE 7.3	0
OP 2.1 CCR5 in HIV Prevention and Cure	0
PP 4.17 – 00198 Peripheral Blood Biomarkers of Occult Infection in ART-Suppressed, SIV-Infected Rhesus Macaques	0
PP 1.5 – 00040 Mapping of genetic interaction networks identifies a nucleosomal modification complex for silencing HIV	0
PP 4.18 – 00213 Dynamics and antiviral role of TOX+ TCF1+ CD39+ CD8 T cells in lymphoid tissue of SIV-infected rhesus macaques	0
PP 2.7 – 00093 Modeling HIV-1 Pathogenesis and Latency in iPSC-Derived Human Cerebral Organoids	0
PP 1.26 – 00143 Understanding HIV transcription in Kaposi's sarcoma tumors during antiretroviral therapy	0
PP 3.6 – 00122 Heterogeneous associations between HIV genomic integrity and proviral longevity during long-term ART	0
PP 3.1 – 00058 Development of a digital PCR assay to profile HIV expression at single-infected-cell resolution	0
OP 2.3 – 00117 The EZH2 inhibitor Tazemetostat increases MHC I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs	0
PP 1.12 – 00076 The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11	0
PP 7.11 – 00091 In vivo and in vitro imaging of viral reservoirs to understand bystander damage during chronic HIV infection	0
PP 4.13 – 00151 Soluble Factors Drive Naïve CD4+ T Cells to Differentiate into CCR5 + Tissue Resident Memory Cells that are Highly Susceptible to HIV infection	0
OP 4.4 – 00018 HIV reservoir burden associates with numbers of HIV-specific CD8+ T cells under long-term antiretroviral therapy and prevents them from differentiating into functional memory cells	0
OP 2.6 – 00135 Constitutive NKG2A levels and timing of antiretroviral therapy initiation impact the potential role of NK cells after treatment interruption - the pVISCONTI study	0
PP 7.8 – 00060 Slowing or Reversal of Decay of Intact Proviruses Over Two Decades of Suppressive ART	0
PP 5.1 – 00045 Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Long-Acting Lenacapavir for Treatment of HIV	0
PP 3.8 – 00137 Characterization of the HIV-1 subtype C reservoir during ART in South-African men and women	0
PP 2.14 – 00162 Elucidating the effects of combination therapy with Venetoclax and IAP inhibitor AZD5582 in SIV-infected, ART-suppressed macaques	0
Highlights of HIV Cure in IAS, Montréal	0
OP 4.3 – 00112 Leaky reservoirs are associated with HIV-specific cd4 and CD8 T-cell responses	0
PP 1.2 – 00011 Structural rearrangements in the nucleus localize latent HIV proviruses to a perinucleolar zone supportive of early transcription reactivation	0
Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom	0
PP 3.7 – 00128 Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes	0
PP 8.7 – 00098 The sequestration and expansion of effector lymphocytes in lymphoid tissue using combination FTY720 and N-803 immunotherapy at ART initiation fails to limit SIV persistence	0
PP 8.8 – 00129 Antibody mediated killing of HIV-1 infected cells with glycoengineered broadly neutralizing antibodies	0
Editorial 6.4	0
Editorial Board	0
Editorial JVE 8.3	0
PP 7.9 – 00073 HIV-1 Cell-Associated RNA Provides 0.8 Prediction Accuracy for Time to Rebound after Treatment Interruption	0
Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya	0
Editorial Board	0
Editorial	0
PP 1.21 – 00118 Regulation of HIV-1 persistence by the CARD8 inflammasome	0
Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV	0
PP 2.13 – 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in “Kick and Kill” HIV Cure Approaches	0
Editorial Board	0
PP 4.15 – 00181 Distinctive cytoskeletal properties are implicated in the resistance of a fraction of productively HIV-infected CD4+ T-cells to killing by cytotoxic T lymphocytes (CTL)	0
Editorial JVE 8.4	0
PP 2.11 – 00144 Transcriptional and translational SIV profiles of peripheral and lymphoid CD4+ T cells of viremic and ART-suppressed Rhesus macaques	0

Editorial JVE 9.3	0
PP 6.1 – 00005 Single cell quantification of hiv-1 and lentiviral vector in gene therapy studies	0
Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk	0
PP 1.33 – 00167 Integrated single-cell multi-omic profiling of HIV latency reversal	0
Editorial JVE 9.4	0
PP 2.3 – 00034 CD8+ T-Cell Sieving During SIV Reactivation from Latency	0
OP 6.5 – 00164 Nanobody-engineered AAV vectors for CD4-targeted gene therapy	0
Antigen specificities of HIV-infected cells: A role in infection and persistence?	0
PP 1.42 – 00114 Functional Polarization of Human Monocyte-Derived Macrophage into M1-Proinflammatory Cells Restricts Both HIV-1 and Zika Virus Replication	0
PP 4.7 – 00097 Signatures of HIV-Infected CD4+ T Cell Resistance to NK Cell-Mediated Cytotoxicity	0
OP 4.6 – 00185 No associations between magnitudes of HIV-specific CTL responses on stable art and subsequent decay of intact proviruses or cell-associated HIV mRNA	0
PP 1.25 – 00136 Daily Variations in Residual Viral Transcription in ART-Treated People Living with HIV-1	0
PP 1.19 – 00109 Differential decay dynamics of the inducible pool of HIV-1 infected CD4+ T cells and proviral DNA upon ART initiation revealed by the novel VIP-SPOT assay	0
PP 3.5 – 00110 The proviral quasispecies of HIV-1	0
OP 5.5 – 00083 Impairment of HIV proviral reactivation by interfering with essential metabolic pathways in effector memory CD4+ T cells	0
PP 4.25 – 00196 The Role of Epigenetics in Mediating Neuronal Circuitry and Maladaptive Neuronal Changes in HIV and Opioid Drug Addiction	0
PP 1.36 – 00182 Effect of HIV-1C Transmitted/Founder Viruses 5′LTRand tat Genetic Variation on Viral Reservoir Size and Latency Reversal Potential	0
PP 1.7 – 00051 Continuous decline of intact proviral DNA after two decades of antiretroviral therapy	0
PP 7.4 – 00016 Acquisition of SARS-CoV-2 infection during an HIV cure study with an ATI period	0
PP 4.4 – 00059 Quantification of HIV Reservoirs in Brain: focus in bystander damage	0
PP 3.16 – 00209 Prolonged persistence of HIV-infected cells in tissues after allogeneic hematopoietic transplant	0
PP 2.17 – 00187 Myeloid-derived extracellular vesicle production is upregulated with SHIV.D infection	0
Conference Report – Recommendations from the Forum for Collaborative Research Symposium on hepatitis B elimination and universal hepatitis B adult vaccination in the United States	0
PP 4.12 – 00141 Enhancement of IL15/IL15RA signaling in immune cells using CRISPR-dCas9-VPR platform	0
PP 1.29 – 00158 The chaperone protein p32 stabilizes HIV-1 Tat and strengthens the p-TEFb/RNAPII/TAR complex promoting HIV transcription elongation	0
Highlights from the virtual conference on retroviruses and opportunistic infections (CROI) 2021: SARS-CoV-2 pathogenesis, new data about antiretroviral treatments, HIV-associated comorbidities, pediat	0
OP 4.2 – 00085 Cytolytic CD8+ T cells infiltrate germinal centers and limit HIV replication in spontaneous controllers	0
PP 3.3 – 00071 Longitudinal proviral landscape and reservoir dynamics in a unique case of HIV superinfection	0
Title Page	0
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial	0
PP 8.5 – 00080 Fc-engineering of anti-HIV-1 antibodies and nanobodies to improve Fc mediated effector functions	0
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers	0
PP 7.10 – 00088 Macrophage-Tropic HIV-1 Variants Contribute to Pediatric Rebound Viremia off ART	0
Editorial Board	0
PP 8.9 – 00142 Safety and activity of BCL-2 inhibitor Venetoclax in uninfected rhesus macaques	0
Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study	0
PP 7.5 – 00032 Changes to microglial genome structure and function in the HIV infected brain	0
HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption	0
Editorial JVE 7.1	0
PP 5.2 – 00072 Simulations for Once Weekly Dosing of Oral Lenacapavir	0
Editorial Board	0
PP 2.12 – 00153 eCD4-Ig-DNA Decreased HIV Reservoir and Delayed Viral Rebound Through Fc Mediated Functions in BLT Humanized Mice	0
Glasgow HIV conference on HIV Drug Therapy 2020	0
PP 3.17 – 00211 Genetic Diversity of HIV-1 Long Terminal Repeat in Proviral Populations During Long-Term Antiretroviral Therapy	0
Editorial	0
OP 2.4 – 00145 No Evidence of Ongoing Viral Replication in SIV-Infected Macaques on Combination Antiretroviral Therapy Initiated in the Chronic Phase of Infection Despite Elevated Residual Plasma Vira	0
Editorial Board	0
Identifying patterns of sexual behaviors and PrEP uptake characteristics among MSM who were eligible for PrEP: A national cross-section study	0
PP 1.14 – 00094 Development of an immunocytochemistry assay to quantify the translationally active HIV reservoir	0
Editorial JVE 9.1	0
PP 2.4 – 00038 Age and biological sex but not sex hormones influence IL-15 biological activity	0
PP 5.4 – 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents	0
PP 1.41 – 00092 Spatial Transcriptomics and the Search for the Latent HIV-1 Cell Niche	0
PP 5.5 – 00026 Targeting Tat/TAR interactions with the superelongation complex for the development of novel treatments for HIV/AIDS	0
Editorial 10.3	0
PP 1.27 – 00147 Role of the pol gene enhancer in HIV-1 transcription and replication in myeloid infected cells	0
PP 3.12 – 00180 Distinct HIV-1 resistance profiles against bNAb in intact vs defective viral genomes	0
PP 3.9 – 00146 Impact of time on antiretroviral therapy on the proviral reservoir in people living with HIV	0
PP 2.1 – 00014 Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques	0
PP 1.18 – 00105 Machine learning identifies differentiating physicochemical signatures between HIV subtypes in Nef domains associated with host-cell regulation	0
PP 8.11 – 00174 Distinct HIV reservoir characteristics among individuals treated during primary versus chronic HIV infection	0
PP 4.11 – 00126 Autologous Neutralizing Antibodies Increase with Early Antiretroviral Therapy and Shape HIV Rebound after Treatment Interruption	0
PP 4.9 – 00113 Transcription of Defective HIV Proviruses Trigger Innate Immune Responses	0
PP 1.23 – 00130 Long-read sequencing assay allows accurate characterization of the HIV-1 reservoir	0
PP 1.9 – 00067 Longitudinal quantification of HIV proviral DNA and host APOBEC3G/-F mRNA expression in cellular subsets that are targeted by HIV-1	0
PP 8.13 – 00191 Investigating the Impact of CD4 mimetic BNM-III-170 on SHIV-infected Rhesus Macaques	0
PP 6.5 – 00205 Utilization of high-throughput assays and deep-learning for selection of CRISPR/Cas9-gRNA pairs used in an HIV-1 cure strategy	0
PP 3.10 – 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment	0
PP 2.16 – 00177 Development of a nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women	0
Highlights of the Conference on Retroviruses and Opportunistic Infections, 12–16 February 2022, virtual	0
PP 4.5 – 00064 Differentiation Enhances Reactivation of Latent HIV-1 Reservoir in CD4+ T Cells in PLWH With > 4 Years of Viral Suppression	0
PP 1.6 – 00047LAIR-1 is a negative regulator of SIV-specific CD8 T cells during chronic SIV infection	0
Editorial JVE 10.2	0
PP 3.11 – 00171 The chromatin insulator CTCF inhibits HIV gene expression	0
Table of Contents	0
PP 8.1 – 00003 Optimization of the 5′ cap and untranslated regions enhances the immunogenicity of an mRNA-based therapeutic vaccine in SIV-infected rhesus macaques on ART	0
Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa	0
PP 7.13 – 00090 Early evolution of HIV-1 from transmitted founders during acute infection	0
Existing knowledge, myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant communities	0
PP 7.12 – 00192 The immune synapses reveal aberrant functions of CD8 T cells during chronic HIV infection	0
Editorial Board	0
Editorial Board	0
Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection	0
PP 1.22 – 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi	0
Vaccination against COVID-19 among healthcare workers as a cocoon strategy for people living with HIV	0
PP 2.15 – 00169 Macrophages are the primary source of virus in semen and male genital tract organs in acutely and chronically infected rhesus macaques	0
Editorial Board	0
OP 5.4 – 00127 Identification and characterization of novel inhibitors of HIV Tat protein	0
Incentivized self-vaccination for global measles eradication	0
PP 2.8 – 00124 Spironolactone Represses HIV-1 Driven Transcription in Human Microglia and T cell Models of Latency and Alters DNA Methylation of Metabolic Genes	0
Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country	0
PP 3.4 – 00079 HIV-1 clade C reservoir characteristics in early and chronic treated infection	0
Vaccines coverage and associated factors among children aged 12–23 months in the Pawie district, Ethiopia: A cross-sectional study	0
PP 1.28 – 00156 The HIV-1 antisense RNA Ast promotes viral latency via epigenetic silencing of the proviral 5′LTR and is expressed in latently infected cells from ART-suppressed donors	0
Editorial Board	0